A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate - PubMed (original) (raw)
Comparative Study
A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate
K Fotherby et al. Fertil Steril. 1980 Aug.
Free article
Abstract
PIP: 2 populations attending WHO centers, one in Sweden and one in India, participated in a comparative, pilot trial of 2 increasingly popular injectable progestin-only female contraceptives, Depo-Provera and Norigest. The purpose of the study was to assess the pharmacokinetic and pharmacodynamic properties of the 2 formulations (depot medroxyprogesterone acetate and norethisterone enanthate). Differences were found between Swedish women and Indian women in their reactions to the 2 drugs: 1) Norigest was detectable in blood samples a significantly shorter time after injection of the agent in Indian women than in Swedish women; this difference was not apparent with Depo-Provera. 2) Although there was no difference at the 2 centers in the time of ovulation return for subjects receiving Norigest, 0 of 4 Swedish women ovulated more than 156 days after Depo-Provera injection, whereas all 4 Indian women ovulated within 73 days of Depo-Provera injection; in the Swedish women, the levels of medroxyprogesterone were undetectable at time of return to ovulation, whereas Indian women had levels of .6 ng/ml when ovulation resumed. 3) In both cultures, Depo-Provera users had significantly more episodes of bleeding and spotting than Norigest users. This preliminary report emphasizes the variety of responses possible to injection of different contraceptive progestins among various populations and points to the need for further culturally comparative studies.
Similar articles
- Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R, Hales HA, Stevenson K, Hatasaka HH, Poulson AM, Jones KP, Peterson CM. Mainwaring R, et al. Contraception. 1995 Mar;51(3):149-53. doi: 10.1016/0010-7824(95)00011-x. Contraception. 1995. PMID: 7621683 - A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I, Khan AR, Jahan FA. Swenson I, et al. Contraception. 1980 Mar;21(3):207-15. doi: 10.1016/0010-7824(80)90001-3. Contraception. 1980. PMID: 6446442 Clinical Trial. - [Prolonged-action contraceptives].
Alipov VI, Korkhov VV. Alipov VI, et al. Akush Ginekol (Mosk). 1987 Sep;(9):7-8. Akush Ginekol (Mosk). 1987. PMID: 3322079 Review. Russian. - Long acting injectable hormonal contraceptives.
Fraser IS. Fraser IS. Clin Reprod Fertil. 1982 Mar;1(1):67-88. Clin Reprod Fertil. 1982. PMID: 6226351 Review.
Cited by
- Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
Singata-Madliki M, Smit J, Beksinska M, Balakrishna Y, Avenant C, Beesham I, Seocharan I, Batting J, Hapgood JP, Hofmeyr GJ. Singata-Madliki M, et al. PLoS One. 2024 Mar 26;19(3):e0295764. doi: 10.1371/journal.pone.0295764. eCollection 2024. PLoS One. 2024. PMID: 38530848 Free PMC article. Clinical Trial. - Long acting contraceptives. Present status.
Benagiano G, Primiero FM. Benagiano G, et al. Drugs. 1983 Jun;25(6):570-609. doi: 10.2165/00003495-198325060-00003. Drugs. 1983. PMID: 6223801 Review. - Misreporting contraceptive use and the association of peak study progestin levels with weight and BMI among women randomized to the progestin-only injectable contraceptives DMPA-IM and NET-EN.
Avenant C, Bick AJ, Skosana SB, Dlamini S, Balakrishna Y, Moliki JM, Singata-Madliki M, Hofmeyr GJ, Smit J, Beksinska M, Beesham I, Seocharan I, Batting J, Chen PL, Storbeck KH, Africander D, Hapgood JP. Avenant C, et al. PLoS One. 2023 Dec 22;18(12):e0295959. doi: 10.1371/journal.pone.0295959. eCollection 2023. PLoS One. 2023. PMID: 38134043 Free PMC article. Clinical Trial. - Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.
Hapgood JP, Kaushic C, Hel Z. Hapgood JP, et al. Endocr Rev. 2018 Feb 1;39(1):36-78. doi: 10.1210/er.2017-00103. Endocr Rev. 2018. PMID: 29309550 Free PMC article. Review. - HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.
Heffron R, Stalter R, Pyra M, Nanda K, Erikson DW, Hladik F, Blue SW, Davis NL, Mugo N, Kourtis AP, Lingappa JR, Baeten JM; Partners PrEP Study and Partners in Prevention HSV/HIV Transmission Study Teams. Heffron R, et al. AIDS. 2019 Mar 15;33(4):735-744. doi: 10.1097/QAD.0000000000002123. AIDS. 2019. PMID: 30585845 Free PMC article.